title: Beneficial effect of one HLA haplo- or semi-identical transfusion versus three untyped blood units on alloimmunization and acute rejection episodes in first renal allograft recipients.
abstract: Acute allograft rejection is the major risk factor of renal function decline and graft loss. Beside histocompatibility matches and pharmacological immunosuppression, blood transfusion is empirically used to detect responder subjects and to induce immune tolerance. Alloimmunization associated with blood transfusions readily detected by anti-HLA antibodies could induce acute vascular rejection episodes during the early period after grafting. Our open prospective study was aimed at analyzing the 1 year follow-up of 105 successive first cadaver renal transplant recipients according to the transfusion protocol as assessed by anti-HLA antibody production, acute rejection episodes, and graft survival. Our conventional transfusion protocol involved 3 nonphenotyped blood transfusions set up at least 20 days before grafting in a control cohort (group A) and was compared with a single pretransplant HLA haplo- or semi-identical blood transfusion in a successive group of patients (group B). Our results suggest that both protocols were associated with similar 1-year graft survivals (> 96% in both groups) and number of patients experiencing rejection episodes (20.7% in group A; 9.6% in group B; P NS). HLA haplo- or semi-identical transfusion was significantly beneficial in naive patients without previous alloantigen contact by pregnancy or blood transfusions during dialysis. Naive patients in group B did not develop post-transfusion anti-HLA antibodies compared to naive patients in group A (16.6%; P < 0.001), and they experienced significantly less acute rejection episodes (2.7%) compared to group A naive patients (20.8%; P = 0.02).
authors.affiliation: Service de Néphrologie, CHU, Grenoble, France.
authors.forename: F
authors.initials: F
authors.lastname: Bayle
authors.forename: D
authors.initials: D
authors.lastname: Masson
authors.forename: P
authors.initials: P
authors.lastname: Zaoui
authors.forename: P
authors.initials: P
authors.lastname: Vialtel
authors.forename: B
authors.initials: B
authors.lastname: Janbon
authors.forename: J C
authors.initials: JC
authors.lastname: Bensa
authors.forename: D J
authors.initials: DJ
authors.lastname: Cordonnier
mesh_terms: D001803:Blood Transfusion; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006680:HLA Antigens / Q000097:blood / Q000235:genetics; D006238:Haploidy; D006801:Humans; D007114:Immunization; D007518:Isoantibodies / Q000276:immunology; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged
chemical_list: D006680:HLA Antigens; D007518:Isoantibodies